Inhibition of CatA: an emerging strategy for the treatment of heart failure.
Future Med Chem
; 5(4): 399-409, 2013 Mar.
Article
em En
| MEDLINE
| ID: mdl-23495688
ABSTRACT
The lysosomal serine carboxypeptidase CatA has a very important and well-known structural function as well as a, so far, less explored catalytic function. A complete loss of the CatA protein results in the lysosomal storage disease galactosialidosis caused by intralysosomal degradation of ß-galactosidase and neuraminidase 1. However, mice with a catalytically inactive CatA enzyme show no signs of this disease. This observation establishes a clear distinction between structural and catalytic functions of the CatA enzyme. Recently, several classes of orally bioavailable synthetic inhibitors of CatA have been identified. Pharmacological studies in rodents indicate a remarkable influence of CatA inhibition on cardiovascular disease progression and identify CatA as a promising novel target for the treatment of heart failure.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Catepsina A
/
Inibidores Enzimáticos
/
Insuficiência Cardíaca
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Future Med Chem
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Alemanha